Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients - a single-institution experience utilising circulating tumour DNA
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Monitoring KRAS/NRAS mutations in metastatic colorectal cancer (CRC) using digital PCR reveals that most patients maintain consistent mutational status, but a third show changes, highlighting the need for continuous molecular testing.
Area Of Science
- Oncology
- Molecular Diagnostics
- Genetics
Background
- Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
- Metastatic disease and recurrence are significant challenges in CRC management.
- Molecular testing, including KRAS/NRAS/BRAF mutations, is crucial for guiding treatment in stage IV CRC.
Purpose Of The Study
- To investigate the mutational landscape of KRAS and NRAS genes in patients with stage IV CRC.
- To assess the utility of digital PCR BEAMing for detecting mutations in circulating tumor DNA (ctDNA).
- To evaluate changes in mutational status during therapy and disease progression.
Main Methods
- Utilized digital polymerase chain reaction (PCR) BEAMing for high-sensitivity mutation detection.
- Analyzed liquid biopsy samples from patients with histologically confirmed stage IV CRC.
- Monitored KRAS and NRAS mutations at baseline, midline, and progression stages.
Main Results
- 66.6% of patients maintained consistent KRAS/NRAS mutational status throughout therapy.
- 33.3% of patients exhibited a shift in their mutational status post-disease progression.
- High-sensitivity techniques like BEAMing Digital PCR are essential for accurate ctDNA mutation detection.
Conclusions
- Continuous molecular monitoring of ctDNA is significant for guiding therapeutic decisions in metastatic CRC.
- Understanding the evolving mutational landscape has clinical implications for personalized cancer medicine.
- Digital PCR BEAMing offers a sensitive method for tracking tumor evolution.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
